Prostate Cancer Diagnostics Global Market Report 2024

Description

Prostate cancer diagnostics involve the process of determining and confirming the presence of prostate cancer through diagnostic testing and medical evaluations. The primary aim is to assess the status and severity of the illness, guiding treatment choices. This diagnostic approach is commonly applied in the treatment of prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors.

The main products in prostate cancer diagnostics include instruments, reagents and consumables, and accessories. Accessories encompass items in the kit that may not be strictly necessary but can enhance effectiveness, such as a prostate-specific antigen (PSA) test kit, biopsy needle, and ultrasound gel, all utilized in the diagnosis of prostate cancer. Various test types, including preliminary and confirmatory tests, diagnose different types of prostate cancers, such as squamous cell cancer, small cell carcinoma, transitional cell cancer, prostatic adenocarcinoma, ductal adenocarcinoma, small cell prostate cancer, and acinar adenocarcinoma. These diagnostic tests are applicable to various age groups, including adults, pediatric, and geriatric populations, and are performed by different end users, including hospitals, independent diagnostic laboratories, cancer research institutes, and others.

The prostate cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer diagnostics market statistics, including prostate cancer diagnostics industry global market size, regional shares, competitors with a prostate cancer diagnostics market share, detailed prostate cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer diagnostics industry. This prostate cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $3.86 billion in 2023 to $4.4 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The expansion observed in the historical period can be attributed to factors such as the increasing aging population, advancements in medical imaging technologies, rising awareness and screening programs, public health initiatives, and improvements in biopsy techniques.

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth in the forecast period can be attributed to the integration of artificial intelligence (AI), the growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, and the utilization of multiparametric MRI for diagnosis. Key trends expected in the forecast period include the adoption of liquid biopsy technologies, technological advances in biomarker detection, increased focus on clinical research and development, integration of digital pathology, and the emergence of multiplex biomarker assays.

The prostate cancer diagnostics market is anticipated to experience growth, driven by the increasing prevalence of prostate cancer. This condition, affecting the prostate gland in the male and female reproductive systems, necessitates early diagnosis through various tests, including prostate-specific antigen (PSA) testing and advanced imaging techniques. In January 2023, the American Cancer Society (ACS) reported an estimated 288,300 new cases of prostate cancer and 34,700 deaths attributed to the disease for the same year. Consequently, the rising prevalence of prostate cancer is expected to fuel the expansion of the prostate cancer diagnostics market.

The growth of the prostate cancer diagnosis market is further propelled by an increase in healthcare spending. Healthcare spending, reflecting the total financial resources allocated to the healthcare sector, facilitates resource allocation for prostate cancer diagnosis. This allocation supports early detection, accurate staging, and timely intervention, aiming to enhance patient outcomes, survival rates, and overall quality of care. According to the American Medical Association (AMA), health spending in the United States increased by 2.7% in 2021, reaching $4.3 trillion or $12,914 per capita. Therefore, the upward trend in healthcare spending contributes to the growth of the prostate cancer diagnosis market.

Technological innovations represent a prominent trend in the prostate cancer diagnostics market, with major companies introducing advanced AI-powered tools for diagnosis. In March 2023, Qritive, a Singapore-based company, launched QAi Prostate-an AI-powered prostate cancer diagnosis tool designed for pathologists. This tool employs sophisticated machine learning algorithms to identify prostatic adenocarcinoma regions and analyze whole slide images of prostate core needle biopsies. The innovative tool facilitates accurate and swift diagnoses, reducing treatment time.

Strategic partnerships are a key approach adopted by major companies in the prostate cancer diagnostics market to advance cancer precision medicine. In March 2022, Lantheus Holdings Inc., a US-based diagnostic and imaging products company, partnered with Novartis AG, a Switzerland-based pharmaceutical company, to utilize Lantheus' prostate-specific membrane antigen (PSMA) imaging agent, PYLARIFY, in clinical trials for Pluvicto. This collaboration aims to enhance the diagnosis of patients with prostate cancer for improved treatment outcomes.

In August 2022, MDxHealth SA, a US-based precision diagnostics company, acquired Exact Sciences Corporation to bolster its leadership in the precision diagnostics urology market. This acquisition expanded MDxHealth's prostate diagnostics business with the inclusion of the Oncotype DX GPS (Genomic Prostate Score) test. Exact Sciences Corporation, a US-based cancer screening and diagnostic tests company, brought valuable assets, including prostate pipelines software supporting patients throughout their cancer diagnosis and treatment.

Major companies operating in the prostate cancer diagnostics market report are F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc., Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., GRAIL Inc., Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd., Exosome Diagnostics Inc., Eurolyser Diagnostica GmbH, Dana-Farber Cancer Institute, Vyant Bio Inc., Cellanyx Diagnostics Inc., A3P Biomedical AB

North America was the largest region in the prostate cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prostate cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer diagnostics market consists of revenues earned by entities by providing transrectal ultrasound, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer diagnostics market also includes sales of products such as tumor biopsies, and test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Products: Instruments; Reagents And Consumables; Accessories
2) By Test Type: Preliminary Tests; Confirmatory Tests
3) By Prostate Cancer: Squamous Cell Cancer; Small Cell Carcinoma; Transitional Cell Cancer; Prostatic Adenocarcinoma; Ductal Adenocarcinoma; Small Cell Prostate Cancer; Acinar Adenocarcinoma
4) By Peer Groups: Adult; Pediatric; Geriatrics
5) By End User: Hospitals; Independent Diagnostic Laboratories; Cancer Research Institutes; Other End-Users
Companies Mentioned: F. Hoffman-La Roche AG; Bayer AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13825

1. Executive Summary

2. Prostate Cancer Diagnostics Market Characteristics

3. Prostate Cancer Diagnostics Market Trends And Strategies

4. Prostate Cancer Diagnostics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Prostate Cancer Diagnostics Market Size and Growth

5.1. Global Prostate Cancer Diagnostics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Prostate Cancer Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Prostate Cancer Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Prostate Cancer Diagnostics Market Segmentation

6.1. Global Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Instruments
Reagents And Consumables
Accessories
6.2. Global Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Preliminary Tests
Confirmatory Tests
6.3. Global Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Squamous Cell Cancer
Small Cell Carcinoma
Transitional Cell Cancer
Prostatic Adenocarcinoma
Ductal Adenocarcinoma
Small Cell Prostate Cancer
Acinar Adenocarcinoma
6.4. Global Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Adult
Pediatric
Geriatrics
6.5. Global Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Independent Diagnostic Laboratories
Cancer Research Institutes
Other End-Users

7. Prostate Cancer Diagnostics Market Regional And Country Analysis

7.1. Global Prostate Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Prostate Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Prostate Cancer Diagnostics Market

8.1. Asia-Pacific Prostate Cancer Diagnostics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Prostate Cancer Diagnostics Market

9.1. China Prostate Cancer Diagnostics Market Overview
9.2. China Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Prostate Cancer Diagnostics Market

10.1. India Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Prostate Cancer Diagnostics Market

11.1. Japan Prostate Cancer Diagnostics Market Overview
11.2. Japan Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Prostate Cancer Diagnostics Market

12.1. Australia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Prostate Cancer Diagnostics Market

13.1. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Prostate Cancer Diagnostics Market

14.1. South Korea Prostate Cancer Diagnostics Market Overview
14.2. South Korea Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Prostate Cancer Diagnostics Market

15.1. Western Europe Prostate Cancer Diagnostics Market Overview
15.2. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Prostate Cancer Diagnostics Market

16.1. UK Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Prostate Cancer Diagnostics Market

17.1. Germany Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Prostate Cancer Diagnostics Market

18.1. France Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Prostate Cancer Diagnostics Market

19.1. Italy Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Prostate Cancer Diagnostics Market

20.1. Spain Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Prostate Cancer Diagnostics Market

21.1. Eastern Europe Prostate Cancer Diagnostics Market Overview
21.2. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Prostate Cancer Diagnostics Market

22.1. Russia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Prostate Cancer Diagnostics Market

23.1. North America Prostate Cancer Diagnostics Market Overview
23.2. North America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Prostate Cancer Diagnostics Market

24.1. USA Prostate Cancer Diagnostics Market Overview
24.2. USA Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Prostate Cancer Diagnostics Market

25.1. Canada Prostate Cancer Diagnostics Market Overview
25.2. Canada Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Prostate Cancer Diagnostics Market

26.1. South America Prostate Cancer Diagnostics Market Overview
26.2. South America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Prostate Cancer Diagnostics Market

27.1. Brazil Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Prostate Cancer Diagnostics Market

28.1. Middle East Prostate Cancer Diagnostics Market Overview
28.2. Middle East Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Prostate Cancer Diagnostics Market

29.1. Africa Prostate Cancer Diagnostics Market Overview
29.2. Africa Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Prostate Cancer Diagnostics Market Competitive Landscape And Company Profiles

30.1. Prostate Cancer Diagnostics Market Competitive Landscape
30.2. Prostate Cancer Diagnostics Market Company Profiles
- 30.2.1. F. Hoffman-La Roche AG
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Bayer AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Thermo Fisher Scientific Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Abbott Laboratories Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Siemens Healthineers AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Prostate Cancer Diagnostics Market Other Major And Innovative Companies

31.1. Becton Dickinson and Company
31.2. Agilent Technologies Inc.
31.3. Hologic Inc
31.4. Biomerieux SA
31.5. Beckman Coulter Inc.
31.6. Qiagen N.V.
31.7. EXACT Sciences Corporation
31.8. Diasorin S.P.A.
31.9. OPKO Health Inc.
31.10. Myriad Genetics Inc.
31.11. Cepheid Inc
31.12. NeoGenomics Laboratories Inc.
31.13. Guardant Health Inc
31.14. GRAIL Inc
31.15. Fujirebio Diagnostics Inc.

32. Global Prostate Cancer Diagnostics Market Competitive Benchmarking

33. Global Prostate Cancer Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Prostate Cancer Diagnostics Market

35. Prostate Cancer Diagnostics Market Future Outlook and Potential Analysis

35.1 Prostate Cancer Diagnostics Market In 2028 - Countries Offering Most New Opportunities
35.2 Prostate Cancer Diagnostics Market In 2028 - Segments Offering Most New Opportunities
35.3 Prostate Cancer Diagnostics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer